Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Oct 27, 2026
TickeronGET DAILY SIGNALS
10x Genomics (TXG): Is a Move to $105 Realistic After Its +348% Surge?

10x Genomics (TXG): Is a Move to $105 Realistic After Its +348% Surge?

Key Takeaways

  • The central target of $105 is the average of verified analyst price targets that sit above the current market price, not the headline consensus.
  • The overall mean of all analyst targets is roughly $77, with a wide range from about $50 to $110, reflecting significant disagreement.
  • With the stock near $73, reaching $105 would require a gain of roughly 44% — a very large move, though the stock traded above $100 as recently as early October 2026.
  • Bullish support comes from the Atera platform launch, growing spatial biology demand, and positioning around AI-driven drug discovery, alongside notable institutional buying.
  • The biggest risks are persistent losses, extreme volatility, a rich valuation, and competitive pressure in single-cell and spatial genomics.
  • For more context, explore the Major News, Today's Price Move, Forecast, and Earnings pages for this ticker.
  • You can also explore Trending AI Robots to see AI-driven trading strategies across the market.

Analyst Price Targets and the Street's View

Roughly 18 to 19 analysts cover TXG, according to S&P Global and Zacks data. Their targets span a wide band from a low near $50 to a high near $110, with an overall average price target of approximately $77. Because that average sits only about 5% above the recent price — too small to pose a meaningful "can it reach" question — the central target used here is instead the average of the verified targets that sit above the current price. Those higher-end targets, which include a $100 target from an October 2026 Buy rating and the $110 top of the range, average out to roughly $105. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Ratings are skewed cautious rather than uniformly bullish: the Street is split between Strong Buy/Buy calls and a large Hold contingent, with no formal Sell ratings. Barclays, Argus Research, Jefferies, Stephens, William Blair, and Canaccord Genuity have carried constructive or initiating Buy-style views during 2026, while UBS, RBC, Piper Sandler, Citi, Cowen, and Leerink have maintained or initiated Hold ratings. The wide $50–$110 range reflects a genuine debate about whether 10x Genomics' new product cycle justifies its re-rated multiple.

Where TXG Stands Today and the Path to $105

As of the late-October 2026 close, TXG traded near $72.96, within a 52-week range of $12.34 to $102.81. Reaching $105 would require a rise of about 44%, a very large move by any conventional measure. Notably, however, the stock touched its $102.81 52-week high on October 6 before a sharp selloff erased roughly a quarter of its value within weeks, so $105 lies just above a level the market has already visited. The path toward it would likely depend on whether the company's Atera platform and spatial portfolio convert analyst enthusiasm into sustained instrument placements and consumables revenue, rather than renewed momentum alone.

Factors That Could Support a Recovery

Several verified factors could support a recovery toward $105. The company is a leader in single-cell analysis through its Chromium platform and in spatial biology through Visium and Xenium, and the newer Atera platform has given analysts a tangible growth driver to model. Positioning around AI-enabled drug discovery has attracted renewed interest, including a sizable 2026 purchase of roughly 222,000 shares by ARK Investment Management. The balance sheet remains comparatively clean, with modest debt relative to equity and a meaningful cash position, giving the company room to invest through its current losses.

Key Risks That Could Stand in the Way

The obstacles are substantial. 10x Genomics remains unprofitable, posting a trailing-twelve-month net loss of roughly $75 million on about $617 million in revenue, with EPS (earnings per share) around -$0.61. The stock's five-year beta near 2.0 underscores its volatility, and its valuation already reflects considerable optimism about future growth that has not yet materialized on the bottom line. Competition in single-cell and spatial genomics could pressure pricing, and any slowdown in academic or biopharma research spending would weigh directly on instrument demand.

Technical Levels Worth Watching

The chart offers clear reference points. The $102.81 early-October high and the psychologically important $100 level form a durable resistance zone that a move toward $105 would need to clear. On the downside, the stock has repeatedly found support near the $67 area during October, a zone that has held through several sharp intraday declines. A sustained break below that support would undermine the bullish technical structure, while a reclaim of $100 would put the central target back in view.

Time Horizon and Catalysts to Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual analysts may apply different assumptions. The most important near-term catalyst is the company's third-quarter earnings report, confirmed for November 5, 2026, which will test the Street's revenue and guidance expectations. Investors should also watch for analyst target revisions, commentary on Atera adoption and consumables pull-through, any changes in institutional positioning, and broader risk appetite for unprofitable, high-beta growth stocks.

Final Assessment

Whether 10x Genomics (TXG) can reach $105 depends less on sentiment than on execution. The target, derived from analyst targets above the current price, implies a roughly 44% advance from about $73 — a demanding climb, though one that merely retests territory the stock occupied in early October. Support comes from Atera, spatial biology momentum, and AI-adjacent demand, while unprofitability, a rich valuation, and intense volatility are the principal obstacles. With the average analyst target near $77 and individual estimates spanning $50 to $110, the Street itself is divided. The November earnings report and any guidance updates are the clearest near-term signposts for whether higher targets regain credibility.

Using Tickeron AI Tools for Research

When I analyze names with this level of volatility, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track shifting conditions across thousands of stocks and ETFs. The signals draw on technical behavior and AI-driven models to flag Buy, Sell, or Hold ideas, which helps me review opportunities and existing positions more efficiently than manual checks alone. This approach has become a regular part of how I stay on top of fast-moving ideas like TXG.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TXG

TXG in downward trend: 10-day moving average broke below 50-day moving average on November 02, 2026

The 10-day moving average for TXG crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 69 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 35 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

TXG moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for TXG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 212 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

TXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.356) is normal, around the industry mean (4.142). P/E Ratio (-100.475) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a life science technology company, which engages in building products to interrogate, understand and master biology

Industry MedicalNursingServices

Industry
N/A
Address
6230 Stoneridge Mall Road
Phone
+1 925 401-7300
Employees
1178
Web
https://www.10xgenomics.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.